Cargando…

Economic burden of brain metastases in non-small cell lung cancer patients in South Korea: A retrospective cohort study using nationwide claims data

Brain metastases (BM) are common in patients with non-small cell lung cancer (NSCLC). However, the pure economic burden of BM is unknown. This study aimed to evaluate the impact of BM on healthcare costs and resource utilization in patients with NSCLC by comparing patients with and without BM. This...

Descripción completa

Detalles Bibliográficos
Autores principales: Shim, Yoon-Bo, Byun, Joo-Young, Lee, Ju-Yong, Lee, Eui-Kyung, Park, Mi-Hai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488774/
https://www.ncbi.nlm.nih.gov/pubmed/36126084
http://dx.doi.org/10.1371/journal.pone.0274876
_version_ 1784792733823533056
author Shim, Yoon-Bo
Byun, Joo-Young
Lee, Ju-Yong
Lee, Eui-Kyung
Park, Mi-Hai
author_facet Shim, Yoon-Bo
Byun, Joo-Young
Lee, Ju-Yong
Lee, Eui-Kyung
Park, Mi-Hai
author_sort Shim, Yoon-Bo
collection PubMed
description Brain metastases (BM) are common in patients with non-small cell lung cancer (NSCLC). However, the pure economic burden of BM is unknown. This study aimed to evaluate the impact of BM on healthcare costs and resource utilization in patients with NSCLC by comparing patients with and without BM. This was a retrospective cohort analysis of South Korean health insurance review and assessment claims data. Patients with stage IIIB or IV NSCLC were identified (March 1, 2013 to February 28, 2018). We compared their two-year and per-patient-per-month (PPPM) healthcare costs and resource utilization with 1:3 propensity score-matched patients without the condition. A generalized linear model was used to estimate the impact of BM and other covariates on healthcare costs. After propensity score matching with the 33 402 newly diagnosed cases of stage IIIB or IV NSCLC, 3435 and 10 305 patients were classified as having or not having BM, respectively. Mean healthcare costs were significantly greater in patients with BM for both the two years (US$ 44 692 vs. US$ 32 230, p < .0001) and PPPM (US$ 3510 vs. US$ 2573, p < .0001). The length of hospital stay was longer in patients with BM (79.15 vs. 69.41 days for two years, p < .0001; 7.69 vs. 6.86 days PPPM, p < .0001), and patients with BM had more outpatient visits (50.61 vs. 46.43 times for two years, p < .0001; 3.64 vs. 3.40 times PPPM costs, p < .0001). The costs of drugs, radiology/radiotherapy, and admission comprised the majority of PPPM costs and were higher in patients with BM. The generalized linear model analysis suggested that patients with BM had significantly increased healthcare costs (by 1.29-fold, 95% confidence interval 1.26–1.32). BM is a significant economic burden for patients with NSCLC. Therefore, it is important to prevent BM in patients with NSCLC to reduce their economic burden.
format Online
Article
Text
id pubmed-9488774
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-94887742022-09-21 Economic burden of brain metastases in non-small cell lung cancer patients in South Korea: A retrospective cohort study using nationwide claims data Shim, Yoon-Bo Byun, Joo-Young Lee, Ju-Yong Lee, Eui-Kyung Park, Mi-Hai PLoS One Research Article Brain metastases (BM) are common in patients with non-small cell lung cancer (NSCLC). However, the pure economic burden of BM is unknown. This study aimed to evaluate the impact of BM on healthcare costs and resource utilization in patients with NSCLC by comparing patients with and without BM. This was a retrospective cohort analysis of South Korean health insurance review and assessment claims data. Patients with stage IIIB or IV NSCLC were identified (March 1, 2013 to February 28, 2018). We compared their two-year and per-patient-per-month (PPPM) healthcare costs and resource utilization with 1:3 propensity score-matched patients without the condition. A generalized linear model was used to estimate the impact of BM and other covariates on healthcare costs. After propensity score matching with the 33 402 newly diagnosed cases of stage IIIB or IV NSCLC, 3435 and 10 305 patients were classified as having or not having BM, respectively. Mean healthcare costs were significantly greater in patients with BM for both the two years (US$ 44 692 vs. US$ 32 230, p < .0001) and PPPM (US$ 3510 vs. US$ 2573, p < .0001). The length of hospital stay was longer in patients with BM (79.15 vs. 69.41 days for two years, p < .0001; 7.69 vs. 6.86 days PPPM, p < .0001), and patients with BM had more outpatient visits (50.61 vs. 46.43 times for two years, p < .0001; 3.64 vs. 3.40 times PPPM costs, p < .0001). The costs of drugs, radiology/radiotherapy, and admission comprised the majority of PPPM costs and were higher in patients with BM. The generalized linear model analysis suggested that patients with BM had significantly increased healthcare costs (by 1.29-fold, 95% confidence interval 1.26–1.32). BM is a significant economic burden for patients with NSCLC. Therefore, it is important to prevent BM in patients with NSCLC to reduce their economic burden. Public Library of Science 2022-09-20 /pmc/articles/PMC9488774/ /pubmed/36126084 http://dx.doi.org/10.1371/journal.pone.0274876 Text en © 2022 Shim et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Shim, Yoon-Bo
Byun, Joo-Young
Lee, Ju-Yong
Lee, Eui-Kyung
Park, Mi-Hai
Economic burden of brain metastases in non-small cell lung cancer patients in South Korea: A retrospective cohort study using nationwide claims data
title Economic burden of brain metastases in non-small cell lung cancer patients in South Korea: A retrospective cohort study using nationwide claims data
title_full Economic burden of brain metastases in non-small cell lung cancer patients in South Korea: A retrospective cohort study using nationwide claims data
title_fullStr Economic burden of brain metastases in non-small cell lung cancer patients in South Korea: A retrospective cohort study using nationwide claims data
title_full_unstemmed Economic burden of brain metastases in non-small cell lung cancer patients in South Korea: A retrospective cohort study using nationwide claims data
title_short Economic burden of brain metastases in non-small cell lung cancer patients in South Korea: A retrospective cohort study using nationwide claims data
title_sort economic burden of brain metastases in non-small cell lung cancer patients in south korea: a retrospective cohort study using nationwide claims data
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488774/
https://www.ncbi.nlm.nih.gov/pubmed/36126084
http://dx.doi.org/10.1371/journal.pone.0274876
work_keys_str_mv AT shimyoonbo economicburdenofbrainmetastasesinnonsmallcelllungcancerpatientsinsouthkoreaaretrospectivecohortstudyusingnationwideclaimsdata
AT byunjooyoung economicburdenofbrainmetastasesinnonsmallcelllungcancerpatientsinsouthkoreaaretrospectivecohortstudyusingnationwideclaimsdata
AT leejuyong economicburdenofbrainmetastasesinnonsmallcelllungcancerpatientsinsouthkoreaaretrospectivecohortstudyusingnationwideclaimsdata
AT leeeuikyung economicburdenofbrainmetastasesinnonsmallcelllungcancerpatientsinsouthkoreaaretrospectivecohortstudyusingnationwideclaimsdata
AT parkmihai economicburdenofbrainmetastasesinnonsmallcelllungcancerpatientsinsouthkoreaaretrospectivecohortstudyusingnationwideclaimsdata